Rowland Thomas Andrew 4

What Happened

• Rowland Thomas Andrew, SVP & Head — Established Brands at ANI Pharmaceuticals (ANIP), was granted 6,021 restricted shares on 2026-02-26 at a grant value of $77.15 per share (total ~$464,520). On 2026-02-28, 628 shares were disposed/withheld at $73.90 per share to cover tax obligations (proceeds/value ~$46,409).
• These transactions are an award (code A) and a tax withholding/disposition (code F), not an open-market purchase or sale for investment reasons.

Key Details

• Grant date and price: 2026-02-26 — 6,021 shares @ $77.15 (grant value ~$464,520).
• Tax withholding/disposal: 2026-02-28 — 628 shares @ $73.90 (value ~$46,409).
• Vesting: Footnote F1 — the 6,021 restricted shares vest in four equal annual installments beginning Feb 26, 2026.
• Additional note: Footnote F2 references shares withheld for tax purposes (exempt under Rule 16(b)-3) related to the vesting of 2,171 restricted shares previously reported.
• Shares owned after transaction: not stated in the Form 4.
• Filing: Report filed 2026-03-02 for period of report 2026-02-26; the filing does not include a late-filing flag in the provided summary.

Context

• This was a restricted stock grant (an award) rather than an open-market purchase — the shares vest over time, so this is not an immediate bullish vote via a buy. The disposal of 628 shares was to cover taxes (routine withholding), which is common when restricted shares vest or are granted. Rule 16(b)-3 exemptions noted in F2 indicate routine tax-withholding treatment for earlier-reported vesting.